CorestemChemon Inc., a South Korean company listed on KOSDAQ under 166480, revealed that significant advancements were observed in a specific subgroup of slow-progressors. Reductions in biomarkers were noted, signaling support for a precision-medicine strategy. These developments could potentially pave the way for an expedited FDA approval pathway. This update was provided by the company on September 17, 2025, underscoring the progress made in their research efforts.